United Healthcare recently made changes that may affect coverage or reimbursement for genetic and molecular testing
Effective November 1, 2017, United Healthcare is implementing an online Prior Authorization program for genetic and molecular testing
The Genentech products affected are:
- ALECENSA® (alectinib)
- COTELLIC® (cobimetinib)
- Herceptin® (trastuzumab)
- KADCYLA® (ado-trastuzumab emtansine)
- PERJETA® (pertuzumab)
- Tarceva® (erlotinib)
- TECENTRIQ® (atezolizumab)
- VENCLEXTA® (venetoclax)
- ZELBORAF® (vemurafenib)
Additional information can be obtained at https://www.uhcprovider.com/en/prior-auth-advancenotification/genetic-molecular-lab.html
©2017 Genentech USA, Inc. So. San Francisco, CA All rights reserved. ACS/102017/0300 11/17
This promotional message is brought to you by Genentech.
